Member Info for sadoldgit

Preferably news from GSK first then CTA would be my view.
The news of GSK with development plans for 737. There has been phenomenal work achieved with 737 and other checkpoint inhibitors for the treatment of HGSOC and BRAC1 and BRAC2. Lung cancer results with trials so far are outstanding.
Whilst we only have 27.5% interest I would prefer news on this front as requires no further investment by Sar, they will be due milestone payments and royalties further down the line. It will give Sar a steady income, more than they receive in fund raising and dilution and for the first time, a nigh guaranteed annual income. All to be paid for by GSK.

That alone should add at least a pound a share increase.

News of CTA financing and commencement of trial dates for 1801, although important, is open to high expectations, rapid rises and slow falls on no news as we have seen in the past, a traders paradise.

The two released separately should see us least 10p per share old money on reasonable news to both fronts. That my opinion.

On top of that we have 1802 and if and when we receive good escalating dose study results, then we will be much higher than 10p per share old money. Much closer to the old money 28p per share i would envisage.

Regards

Two news fronts.

Preferably news from GSK first then CTA would be my view.
The news of GSK with development plans for 737. There has been phenomenal work achieved with 737 and other checkpoint inhibitors for the treatment of HGSOC and BRAC1 and BRAC2. Lung cancer results with trials so far are outstanding.
Whilst we only have 27.5% interest I would prefer news on this front as requires no further investment by Sar, they will be due milestone payments and royalties further down the line. It will give Sar a steady income, more than they receive in fund raising and dilution and for the first time, a nigh guaranteed annual income. All to be paid for by GSK.

That alone should add at least a pound a share increase.

News of CTA financing and commencement of trial dates for 1801, although important, is open to high expectations, rapid rises and slow falls on no news as we have seen in the past, a traders paradise.

The two released separately should see us least 10p per share old money on reasonable news to both fronts. That my opinion.

On top of that we have 1802 and if and when we receive good escalating dose study results, then we will be much higher than 10p per share old money. Much closer to the old money 28p per share i would envisage.

Regards

Two news fronts.

Agree 100% HbD

Almost back to 5p in old money!

Tyk 2 Jak1 would appear to fit the bill very nicely in my somewhat limited opinion. We also have miniscule amount ofJak2 and Jak 3 as is virtualy impossible to have a specific Jak family member ( ie only selectivity over only) with the exception of Tyk2 of course.

Regards

In this aspect GSK would be clued up on 737 and could offer X amount of money. The question being is do GSK know sufficient about 1801 and 1802 to make anywhere near an acceptable offer? If they chose to take over a company they will need to know all about its pipeline just as they did with SO. The only way they can gain that info is become one of Sareums interested parties that they are in regular conversation with.

When GSK bought SO and its on license for 737 they would already be aware of the licensing arrangements, milestone payments and Royalties.

GSK massive company, with a huge pipeline. Yes they want to corner the immuno ocology market. It takes time and you will certainly not gain by buying without doing due diligence first. That takes time and negotiations. Am of the opinion that they will be keeping a very close eye on dose escalation studies as this includes bio markers that will indicate which indications 1801 are likely to be the most successful in.

Regards

As GSK are aware of Sareum for involvement in development of 737 and now very likely to know there immuno oncology compounds then yes it is possible for them to make a bid for the Cambridge Biotec. They are after all the owners of the license for 737 and will be aware not only of the development but also the potential. GSK keen to corner the immuno oncology market as per their website statements.
Niraparib and 737 already has much work completed with great results in combo.

Early days but would not rule out.

Regards

Michelle Garrett overcoming resistance to CHK1 inhibitors. Outstanding research May 2021.

Within 9 months GSK buyout Sierra.
The potential market for CHK1 in Ovarian, Breast and Lung dwarfs the market of Momo. Combo the way forward with two combo treatments patented.

Products hotting up on all fronts I feel. Not sure which is hottest 737 or 1801 but 737 would make first to clinic.

Regards

A list of links relating to development of CCT245737, well worth and advised investor reading.

https://www.lse.co.uk/rns/SAR/chk1-approved-for-clinical-trials-m6rlfubfm1yszri.html

https://www.lse.co.uk/rns/SAR/clinical-trials-chk1-inhibitor-cct245737-to-open-rlxm7f8i83is179.html

https://www.lse.co.uk/rns/SAR/licence-agreement-for-chk1-inhibitor-cct245737-xyagc0y38qg1z9d.html

https://www.lse.co.uk/rns/SAR/chk1-clinical-trials-update-oljt11x3924v05p.html

https://www.lse.co.uk/rns/SAR/sierra-oncology-to-host-call-on-chk1-inhibitor-7z9lmrjowoxghpd.html

https://www.lse.co.uk/rns/SAR/sierra-reports-preclinical-data-for-chk1-inhibitor-qbnqicz0ptvm1t0.html

https://www.lse.co.uk/rns/SAR/preclinical-synergy-of-sra737-and-parp-inhibitor-camo4kchno1nvak.html

https://www.lse.co.uk/rns/SAR/sierra-oncology-expands-sra737-development-program-v3q9hapmg2hcwrj.html

https://www.lse.co.uk/rns/SAR/late-breaker-abstract-for-sra737-accepted-for-aacr-au72046fkbn6wjh.html

https://www.lse.co.uk/rns/SAR/sra737-trial-update-in-sierra-oncology-q1-results-6unap1wejs4ybij.html

https://www.lse.co.uk/rns/SAR/preclinical-data-for-sra737-in-ovarian-cancer-tnzrjtlktinkyg6.html

https://www.lse.co.uk/rns/SAR/new-sra737-preclin-data-to-be-presented-at-aacr-9ww9jrs7esz802z.html

https://www.lse.co.uk/rns/SAR/positive-sra737-data-presented-at-asco-5udbqpz5q0z7qn8.html

https://www.lse.co.uk/rns/SAR/key-takeaways-from-sra737-webcast-at-asco-6twexv6wzo0q0mr.html

At this moment Sierra after doing Sterling work on 737 have concentrated all their resources on Momo.
Sierra also stated that 737 may prove to be more commercially viable than Momo.
Sierra aslo in 2020 had combo therapy with 727 patented
Michelle Garrett also carried out phenomenal research and work on chk1 inhibitors and proposed methods to overcome them with P13K and ATK inhibitors.

GSK will be filling their boots. Is it any wonder WIP pointed out 737 all password protected.

Regards all.

Also worthy of note is that the CTA is not just shown to be granted, but also how and when funded.

Regards

Just a post here regarding previous clinical trials with CCT245737. it would appear that funding has been provided prior to commencement of clinical trials.

Regards

CHK1 Clinical Trial Applications 15th Dec 2015

Sareum, the specialist cancer drug discovery and development business, is pleased to announce that it has received formal confirmation from its co-development partner, the CRT Pioneer Fund, that Clinical Trial Applications for Phase I clinical trials of CCT245737, the CHK1 Programme clinical development candidate drug, are intended to be submitted to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in January 2016. In accordance with the CHK1 co-investment agreement, Sareum will therefore satisfy its next financial contribution, in respect of its 27.5 per cent investment share, of £797,500 by 29 December 2015.

https://www.lse.co.uk/rns/SAR/chk1-clinical-trial-applications-o5vaeos0sipwihl.html

As reported in the Company's Final Results in October 2015, two clinical trials in cancer patients are planned, one with CCT245737 as a single agent and one in combination with standard-of-care chemotherapy. The funds required for the Company's financial contribution to these trials will be met from existing cash resources.

1st Feb 2016
As reported previously, two clinical trials in cancer patients are planned, one with CCT245737 as a single anti-cancer agent and one in combination with standard-of-care chemotherapy. Once approval is obtained, these trials will be funded in collaboration with co-development partner, the CRT Pioneer Fund. In accordance with the CHK1 co-investment agreement, Sareum satisfied a financial commitment of £797,500 to the funding of this development phase in December 2015.
https://www.lse.co.uk/rns/SAR/chk1-clinical-trial-application-submissions-qltuc9dkas38tpe.html

Subject to final NHS approval, clinical trials are expected to begin in Q2 2016. Two Phase I clinical trials in cancer patients are planned, in collaboration with co-development partners, the CRT Pioneer Fund. One trial will use CCT245737 in combination with standard-of-care chemotherapy and will ultimately target lung and pancreatic cancer patients. The other trial will use CCT245737 as a single anti-cancer agent and will initially target various cancers.

https://www.lse.co.uk/rns/SAR/chk1-approved-for-clinical-trials-m6rlfubfm1yszri.html

Johnnyk
You did not state that Tim had said anything. That is true.
That was not what l asked. I requested where had Tim stated?
You posted Tim had stated (on a new sentence beginning with GSK).
A bit pedantic of me but, l not keen when people post information which can be very misleading.
Need be careful how we word things.

Regards

Johnnyk how are GSk shares related to Sareum? Something l may have missed but, could you point out where Tim stated they would go no less than 3 shares for every 4 of Sareum.

Excuse my ignorance but this is making no sense to me. GSK have bought out Sierra Onclogy ( previously as Pronai Therapeutics) who owned the on licence to CCT245737 from the CPF. They have nothing else to do with Sareum until we are notified to the contrary via RNS.

Regards

it went from circa 14 to 22 dollars if memory serves me correct. Over a relative short period of time. After the price target of 55 dollars was set it went up all of a sudden.
Many silmilarities here. I could see no significant effort in Sierra raising money for milestone payments due to Gilead for Momo. Exception here employees able to purchase discounted shares.

Definate stirrings of some sort going on.

It is eerily quiet on the news front Ahfam.
Sareum will be aware of CTA result which looking at the way they work will be positive.
A delay perhaps as may well be setting up actual recruitment dates and a date to commence trials. If this is the case then I think a little odd as they would have pencilled in dates from date of application.
Bare with me here. Sareum a short while ago stated intention of 1a trials in Q4 and 1b to commence in 2023.
I would hazard a guess that Sareum are currently undertaking negotiations for funding either through investors or partnership/on license.
Sareum have been consistent with raising funds before the money is actually needed.
If we also take into account that the CTA is for 1a and 1b. Sareum can fund 1a but would still have to give a pretty detailed explanation even though they have sucessfully raised funding in the past. This process may be going through at the moment.
How will it be funded?
Who will be funding it?
Proof of this.

Should this be the case then we will be notified by RNS. The longer it goes on without news then the more likely I believe this is the scenario.

In addition there may be due soon milestone payments from GSK regarding 737

Pursuant to the CRT License Agreement, Sierra made a one-time upfront payment of $7.0 million to CPF in October 2016 and paid $2.0 million to CPF in January 2017 for the successful transfer of two ongoing Phase 1 clinical trials. Sareum received a total of approximately $2.5 million from these payments.

Under the terms of the original CRT License Agreement, additional milestone payments of up to an aggregate of $319.5 million were payable to CPF upon the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $7.5 million upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the United States, and a payment of $12.0 million upon the dosing of the first patient of a randomised Phase 2 trial of SRA737.

Pursuant to the terms of the Amendment, Sierra and CPF have agreed to a decrease in the additional milestone payments of up to an aggregate of $290.0 million that may be payable to CPF upon the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $2.0 million upon the dosing of the first patient of the first trial of SRA737 following the Amendment.

In the event that the milestone payment for a milestone event, as defined in the CRT License Agreement, becomes due, but no milestone payment for an earlier milestone event has been paid, then the milestone payment attached to the earlier milestone event will automatically become due and payable contemporaneously with the payment for the later milestone event. Sierra will accrue for any future milestones payments once they are considered probable of occurring.

Not sure how we stand with the CPF 12m dollar payment for later milestone payment.
Regards

you will require level 2 dj.

Nothing from 28th of July apart from 2 price monitoring extensions and a note of TYK2 approval from a competitor.
Discussions of partnership and or on license maybe.
Clearly Sareum know the outcome of the CTA decision.
What else they waiting for?
The suspense, beer time for me.

Should tick up a little I feel.
Silence is deafening.

You are welcome fearg.
Easily done.

Deucravacitinib expectations of 4 billion turnover a year.
We are behind in development, but may prove to have far greater efficacy than what is out there so far. TYK2 is good.
Janus kinase inhibitors work best in pairs.
I would hazard a guess that the miniscule amount of Jak1 we have and far lesser Jak2 and Jak3 we carry will prove to be advantageous, especially in IBD.
Jak1 we already know in theory to give better efficacy than Tyk2 alone.

Regards

Correct fearg. I think your figure should be 1 billion as opposed to 1 million.
Yes it were Lupus (Systemic lupus erythematosus (SLE))

Further good signs of TYk2 for Ventyx bio sciences below. However I do not think it will cut the mustard with IBD as previous phase trials with BMS a specific Tyk 2 allosteric kinase inhibitor failed in IBD

https://ca.style.yahoo.com/ventyx-biosciences-announces-positive-topline-200100508.html

https://pharmaphorum.com/news/failed-ibd-trial-dents-confidence-in-bms-deucravacitinib/

Both the above worth a read. also have turnover expectations.

Tim thinks we are better at psoriasis than Deucravacitinib.

All looking very good for 1801 of which dose escalation trials will prove pivotal.

Tyk 2 Jak1 and very selective over Jak2 and Jak3.